Regenerative Medical Solutions Inc. (RMS) news

Human induced pluripotent stem cell-derived beta-cells for drug and toxicity testing.

Diabetes drug screening platforms using patient pancreatic islet-like cells generated from induced pluripotent stem cells.

Development of a safer stem cell-based diabetes therapy via suicide gene-mediated ablation of proliferative cells.

Evaluation of a beta cell replacement therapy combined product that avoids the need for immunosuppression via localized induction of immune tolerance.

Engineered pancreatic endocrine cells that report beta cell toxicity for use in high throughput screening applications.

Development of a rapid and inexpensive luciferase-based high throughput screening assay to identify compounds that alter pancreatic β cell function.